Prophylactic Dimenhydrinate for Intraoperative Nausea and Vomiting

Samuel Lunenfeld Research Institute, Mount Sinai Hospital

Status

Completed

Conditions

Vomiting

Nausea

Treatments

Other: Placebo

Drug: Dimenhydrinate

Study type

Interventional

Funder types

Other

Identifiers

NCT00791960

08-0206-A

08-01

Details and patient eligibility

About

The purpose of this study will be to determine whether an intravenous dose of dimenhydrinate (also known as Gravol), given before the induction of spinal anesthesia, will decrease the incidence of intraoperative nausea and vomiting in patients undergoing Cesarean delivery.

This medication is commonly given during and after the surgery if required, but it is not known whether a preventative dose will decrease the overall incidence of these side effects.

Full description

Nausea and vomiting remain one of the most common complications of Cesarean delivery. The results of this study will show whether or not we can improve our present anesthesia regimen, and improve the satisfaction of patients undergoing Cesarean deliveries, by reducing the incidence of nausea and vomiting. Our current practice is not to use any medication for preventing nausea and vomiting unless required. However, nausea and vomiting come quite fast and unexpectedly during the operation, and most of the time the medication we give does not work fast enough. We are planning to study the anti-nausea medication dimenhydrinate (commonly known as Gravol), which has been safely and widely used during pregnancy, labour and Cesarean deliveries, hoping that its use will decrease the incidence of this unpleasant occurrence.

Enrollment

149 patients

Sex

Female

Ages

18 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

All patients undergoing elective Cesarean deliveries under spinal anesthesia.
All patients who gave written informed consent to participate in this study.
ASA I and II patients.
Full term normal pregnancy.

Exclusion criteria

All patients who refuse to give written informed consent.
All patients who claim allergy or hypersensitivity to dimenhydrinate.
Patients with history of vomiting within 24 hours prior to Cesarean delivery.
Patients with history of gastrointestinal or psychiatric diseases and morbid obesity
Patients receiving any of the following drugs within 24 hours before the study: opioids, antiemetics, H2 antagonists, phenothiazine and corticosteroids.
Patients with severe pregnancy induced hypertension